Mind Medicine (MindMed) Inc. announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers. The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal. MM-110 (also known as zolunicant HCl or 18-MC) is an a3ß4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.

A total of 72 participants received up to 325 mg of MM-110 (n=51) twice on a single day or placebo (n=21), and 36 participants were administered up to 90mg of MM-110 (n=26) twice daily for seven days or placebo (n=10). The topline results and observations include the following: MM-110 was well-tolerated up to 500mg per day in the single ascending dose (SAD) arm and 60 mg per day for seven days in the multiple-ascending dose (MAD) arm of the trial. A linear pharmacokinetic profile was maintained across the tested doses and frequencies.

Observed clinical effects demonstrated alignment with potent CNS engagement. No serious adverse events were reported. Treatment emergent adverse events were mild or moderate in severity and resolved without sequelae.

Clinical laboratory parameters and electrocardiograms were also assessed with no findings of clinical concern across the administered dose ranges. Next steps: Consistent with the Phase 1 trial and aligned with the preclinical data, an every-other-day dose regimen is planned for the Phase 2a trial. This dose schedule offers the potential to be a better option than existing treatments for supervised opioid withdrawal.

About the Phase 1 Trial Design: The Phase 1 single and multiple-ascending dose trial conducted at a single clinical research site in Perth, Australia, evaluated the safety, tolerability, pharmacokinetics, and effects on the neurocognitive activity of MM-110 in 108 healthy volunteers.